eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2015
vol. 32
 
Share:
Share:
more
 
 
abstract:
Original paper

Serum IL-17A in Behçet’s disease

Nazan Emiroglu
,
Fatma Pelin Cengiz
,
Gul Bahar Erdem

Postep Derm Alergol 2015; XXXII (5): 358–361
Online publish date: 2015/10/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: Behçet’s disease is a chronic multisystem disease with spontaneous remissions and relapses. Several studies show that autoimmune mechanisms play an important role in the development of Behçet’s disease. Activation of T cells and neutrophils is important in the pathogenesis of the disease. Interleukin 17 (IL-17) is a new cytokine that induces several types of cells to secrete proinflammatory cytokines in many inflammatory and autoimmune diseases.

Aim: This study evaluated the serum levels of IL-17A in active and stable Behçet’s disease patients.

Material and methods: Seventy-six patients who had active clinic findings of Behçet’s disease were enrolled in our study. Seventy age- and sex-matched controls were also enrolled. Serum IL-17 levels were studied in peripheral venous blood samples.

Results: No significant differences were found between active Behçet’s disease patients and controls in terms

of serum IL-17A (p > 0.05).

Conclusions: These results suggest that IL-17A serum levels do not play an important role in active Behçet’s disease.
keywords:

active, Behçet’s disease, interleukin 17

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe